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Recent studies suggest that effector T cells generated by
immune responses migrate to multiple non-lymphoid sites,
even those without apparent expression of antigen or inflam-
mation. To investigate the ability of distinct CD4 T lympho-
cyte subsets to enter and persist in non-lymphoid, nonin-
flamed compartments, we examined the migration and
persistence of naı¨ve, effector, and rested effector CD4 T
cells generated in vitro following transfer to nonimmunized
adoptive hosts. Th1 and Th2 effectors migrated to both
lymphoid and non-lymphoid organs (peritoneum, fat pads,
and lung). In contrast, rested effectors and naı¨ve cells
migrated only to lymphoid areas. Adhesion molecule expres-
sion, but not chemokine receptor expression, correlated with
the ability to enter non-lymphoid sites. Donor cells persisted
longer in lymphoid than in non-lymphoid sites. When hosts
with naı¨ve and memory donor cells were challenged with
antigen, effectors developed in situ, which also migrated to
non-lymphoid sites. Memory cells showed an accelerated
shift to non-lymphoid migration, in keeping with memory
effector formation. These results suggest that only recently
activated effector T cells can disperse to non-lymphoid sites
in the absence of antigen and inflammation, and as effectors
return to rest, they lose this ability. These data also argue that
memory cells in lymphoid sites are longer lived and not in
equilibrium with those in non-lymphoid sites.
Naı¨ve T cells are found concentrated in lymphoid organs
such as lymph nodes and spleen, but they constantly recircu-
late, thus providing an effective surveillance system in the
lymphoid organs. The naı¨ve T cells enter the lymph nodes from
the blood via the high endothelial venules and pass through the
paracortex, a specialized T cell compartment. The high surface
expression of CD62L and the chemokine receptor CCR7 on
naı¨ve T cells are associated with their migration into the lymph
node by binding the peripheral lymph node addressin or Gly-
cam-1 and by binding constitutively produced chemokines
such as SLC (CCL21) or ELC (CCL19), respectively (1). When
an immune response occurs, antigen-presenting cells (APC)2
bearing specific peptides, especially activated dendritic cells
(DC), are induced to migrate from the site of infection to the
draining lymph node or spleen, where the naı¨ve T cells first
recognize antigen on DC and are activated to initiate their
response (2).
Optimum activation of naı¨ve cells in lymph nodes requires
signals through the T cell receptor (TCR) via peptide bound to
class II MHC as well as secondary signals from costimulatory
ligands such as B7 and CD40 provided by activated DC. The
combination of these signals leads to proliferation of naı¨ve cells
and begins the process of their differentiation to fully functional
effectors capable of secreting high levels of cytokines and par-
ticipating in helper and inflammatory reactions. The presence
of polarizing cytokines such as IL-12 or IL-4 causeCD4Tcells
to differentiate intoTh1 orTh2 cells that produce distinct cyto-
kine patterns and mediate different types of protective
responses (3, 4). Effector CD4 T cells are also characterized
phenotypically by a decrease in the expression of CD62L and a
concomitant increase in CD44 expression.
Once effector cells are generated, their functional role
requires that they relocate so they can interact with responding
B cells and provide help (5) and/or to migrate to the sites of
infection (6). Evidence indicates that these relocations are reg-
ulated by the acquisition or increase in expression of multiple
adhesionmolecules (7, 8) and a switch in the pattern of chemo-
kine receptor expression (9) that causes the effectors tomigrate
to the B cell zones in lymphoid organs on one hand, or to exit
the lymphoid organ and traffic to sites of infection and inflam-
mation on the other hand. Lymphocytes also widely dissemi-
nate to siteswith no apparent involvement in the response (10–
14). Some recent evidence supports the concept that migration
to these non-lymphoid sites is independent of antigen (10) but
is increased by inflammation (8, 11).
In the infection models examined previously (13, 14), it is
difficult to determine whether migration to tertiary, non-lym-
phoid, sites is an inherent property of effector cells because of
their activation state and surface phenotype, or whether effec-
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tor cells are called into these sites by inflammatory signals
and/or small amounts of antigen. The published studies favor
the idea that some recruitment may be independent of antigen
and inflammation (11) but cannot rule out those factors. The
wide dissemination of effectors could provide an important
mechanism for the destruction of infected cells, which are in or
have gone to non-lymphoid tissues.
Recently it has been demonstrated that during a vigorous
response, highly activated CD8 and CD4 T effectors not only
can migrate widely but they can also persist in these tertiary
sites for months following infection (11, 13, 14). When effector
responses to influenza are visualized in vivo, large numbers of
effectors are recruited to the lung at the peak of effector gener-
ation, and then as soon as virus is cleared, the population rap-
idly contracts and the remaining cells acquire a more resting
phenotype (6). CD4 memory T cell persistence in lymphoid
sites does not require antigen (16). It has been claimed that
memory cells in the site of likely infection are better able to
provide protection.However, the role of antigen and inflamma-
tion in the persistence of primed cells in the non-lymphoid sites
remains unclear.
Our laboratory has demonstrated previously that CD4 T
cell effectors generated in vitro and transferred into recipient
mice can persist as memory cells (15). We found that when in
vitro generatedCD4Tcell effectors are further cultured in the
absence of antigenic stimulation, they revert to a resting state
that phenotypically resembles memory cells (16, 17). When we
adoptively transferred these “rested effector” cells, they
migrated mainly to lymphoid sites and efficiently developed
into long livedmemory cells, which persist indefinitely without
the need for any further division (17). This raises the possibility
that recruitment to non-lymphoid sites is restricted to highly
activated effectors. To better understand the mechanisms gov-
erning non-lymphoidmigration of CD4T cell subsets to non-
inflamed sites, we compared the ability of naı¨ve, Th1 and Th2
effectors, and rested effectors to migrate in an unimmunized
adoptive host. CD4 cells were isolated from TCR transgenic
mice, and effectors were generated in vitro.
Here we report that localization of CD4 T cell effectors to
non-lymphoid organs can occur in the absence of antigen and
inflammatory signals. We find that after transfer to uninfected
hosts, activated, but not rested, effectors migrate in substantial
numbers into tertiary sites. Furthermore, in vivo effectors, gen-
erated following in situ immunization with antigen in adjuvant,
are also recruited into non-lymphoid organs. Resting memory
cells became effectors more quickly following immunization
and also are induced to migrate to tertiary sites. These results
suggest that the ability to migrate to tertiary sites is an intrinsic
but transient property of effectors. Of particular interest is that
populations in the tertiary sites decay faster than those in sec-
ondary sites, arguing against the concept that memory cells
continuously recirculate from tissues to lymphoid organs. We
speculate that the ability of activated effectors to gain access to
noninflamed organs or tissues may be a way to provide amech-
anism to find and destroy disseminated infected cells and pro-
vide systemic protection from reinfection, but that such cells
could also pose a danger by inducing autoimmunity in sites not
normally exposed to immune reactions.
MATERIALS ANDMETHODS
Mice—AND.Thy 1.1 (H-2b/k) and GFP.AND (H-2k/k) TCR
transgenic mice at 6–8 weeks of age were used to obtain donor
cells and were transferred to recipient B10.BR B6 F1(H-2b/k)
or B10.BR (H-2k/k) mice, respectively. All mice were bred in the
animal facility at Trudeau Institute. The animals were kept in
animal isolators in an infection-free environment. Hosts were
intact mice or adult thymectomized, bone marrow reconsti-
tuted mice (ATXBM) that were prepared by surgical thymec-
tomy at 3–4weeks of age, followed by irradiationwith 950 rads,
and bone marrow reconstitution at 1–3 weeks after surgery.
Donor cells were transferred into ATXBM hosts at 1–3 weeks
after bone marrow reconstitution. All animals were bred in the
animal facility at Trudeau Institute. In all experiments,multiple
animalswere analyzed individually, and themean percentage of
total donor cells recovered S.D. was calculated.
Reagents—Medium used for all in vitro cultures was RPMI
1640 (Invitrogen) supplemented with 200g/ml penicillin, 200
g/ml streptomycin, 4 mM L-glutamine, 10 mM HEPES, 5 
105 M 2-mercaptoethanol, and 7.5% fetal calf serum
(Invitrogen).
Preparation of CD4 Naı¨ve T Cells—Naı¨ve CD4 T cells
were enriched from spleen and lymph nodes as described pre-
viously (15). Briefly, pooled spleen and lymph node cells from
TCR Tg mice were passed through a nylon wool column. The
nonadherent cells were then treated with a panel of antibodies,
including anti-CD8 (3.155), anti-heat-stable Ag (J11d), and
anti-class II MHC (D3–137, CA4, and M5114) followed by
complement. The resulting CD4 T cell population was then
further purified into the small resting fraction by Percoll gradi-
ent separation. The purified cell populations were routinely
90% CD4 T cells, 95–98% of which had a naı¨ve phenotype
(CD45RBhi, CD62Lhi, CD44lo, and CD25lo) and expressed the
TCR transgene. Five 20 106 naı¨ve cells were adoptively trans-
ferred by intravenous injection into syngeneic intact or
ATXBMmice.
Generation of Effectors, Rested Effectors, and Memory Cells—
Th1 and Th2 effectors and rested effectors were generated as
described previously (15, 17). Highly purified naı¨ve cells (1.5
105/ml) from AND TCR Tg mice were cultured with mitomy-
cin C (100 g/ml)-treated fibroblast APC expressing B7 and
ICAM-1 (DECK.ICAM) (7.5 104/ml) and 5 M pigeon cyto-
chrome c fragment, amino acids 88–104 (PCCF). For the gen-
eration of Th1 effectors, cultures were incubated with IL-2 (11
ng/ml), IL-12 (2 ng/ml), and anti-IL-4 (clone 11B11; 10g/ml).
Th2 effectors were cultured in the presence of IL-2 (50 units/
ml), IL-4 (200 units/ml), and anti-interferon- (clone XMG1.2;
10 g/ml). Effectors were harvested after 4 days of in vitro cul-
ture, whereas rested effectors were thoroughly washed and
recultured in fresh medium for another 2–3 days. 1–10  106
effectors or rested effectors were adoptively transferred intra-
venously into intact or ATXBMmice.
After we had transferred the effectors, they returned to resting
cells within a few days.3 We refer to the donor cells remaining 3
weeks or more after effector transfer as memory cells (16, 17).
3 J. Li, H. Hu, and S. L. Swain, unpublished data.
Migration of Activated and Resting T Cells
MARCH 2, 2007•VOLUME 282•NUMBER 9 JOURNAL OF BIOLOGICAL CHEMISTRY 6107
 by guest on D
ecem
ber 17, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Immunofluorescent Staining and FACS Analysis—Single cell
suspensions from spleen, lymph nodes, fat pads, PEC, and PBL
were incubated with Cy-Chrome-labeled anti-CD4 (clone
RM4-5; Caltag, Burlingame, CA) and biotin-labeled anti-Thy
1.1 (clone OX-70; Pharmingen) followed by streptavidin APC
(Pharmingen) to detect donor cells. PE-labeled anti-CD44
(clone IM7; Pharmingen) and biotin-labeled anti-CD62L (clone
Mel 14; Caltag) were used to detect surface expression of CD44
and CD62L. Anti-CD11a, anti-CD18, and anti-CD162 were
also from Pharmingen. Control isotype-matched antibodies,
including PE-labeled rat IgG2a, and fluorescein isothiocyanate-
and PE-labeled rat IgG2b isotypes were also purchased from
Pharmingen and used as controls with relevant staining
reagents. Donor cells were gated as Thy1.1/CD4 or GFP/
CD4 cells and were analyzed for the expression of CD44 and
CD62L using FACSCalibur flow cytometers, and the data per-
cent recovery in each organ was based on total donor cells (the
% in FACS analysis total cell recovery from the organ or site)
as a fraction of total transferred cells. This also results in nor-
malized data that can be directly compared from mouse to
mouse and experiment to experiment. The raw data cannot be
so compared, because the number of cells transferred varied in
different experiments.
RNase ProtectionAssay—Total RNAwas isolated fromnaı¨ve,
Th2 effectors, Th2 rested effectors, and Th2 in vivo memory
cells using TRIzol (Invitrogen). mRNA levels were determined
using the RiboQuant multipurpose ribonuclease protection
assay system (Pharmingen) and the mCR-5 (CCR receptors)
and mCR-6 (CXCR receptors) probe sets. The signal from
bands was detected using the densitometric feature of Quantity
One software (Bio-Rad) and normalized against the housekeep-
ing gene L32.
Antigen Challenge of Adoptive Hosts with Naı¨ve, Rested Effec-
tors, and Effectors—In some experiments, adoptively trans-
ferredmice were injected intraperitoneally with 88g of PCCF
peptide emulsified in complete Freund’s adjuvant (CFA) (for
recipients of naı¨ve cells) or incomplete Freund’s adjuvant (IFA)
(for recipients of rested effectors and effectors). The animals
were sacrificed on day 4 after immunization and analyzed for
the presence of transferred cells in spleen, lymph nodes (para-
aortic, inguinal, and mesenteric), PEC, and fat pads.
RESULTS
Th1 and Th2 Effector Cells Migrate to Both Lymphoid and
Non-lymphoid Sites following Adoptive Transfer—Our labora-
tory (6) as well as others (7, 10, 11, 14, 18) have demonstrated
that T cell effectors activated by infection or antigen in adjuvant
canmigrate to the site of inflammationwhere they secrete cyto-
kines, display cytolytic activity, and participate in pathogen
clearance. To analyze the regulation of CD4 T cell subset
recruitment to non-lymphoid sites, we used a standard in vitro
activation protocol to generate Th1 and Th2 effector cells that
produced interferon- and IL-4, respectively (15, 17, 19). After
4 days, the resulting Th1 and Th2 populations were transferred
intravenously into unimmunized intact or ATXBM.We trans-
ferred the CD4 T cell subsets to unimmunized mice where
there would be no possibility of antigen or significant inflam-
mation in non-lymphoid sites. Utilization of TCR Tg cells acti-
vated in vitro and transferred to mice without infection allows
us to determine whether migration to non-lymphoid sites is an
intrinsic property of activated effector cells or results from
inflammation and/or antigen.
The donor Th1 and Th2 effectors were obtained from
Thy1.1 TCR transgenic mice and were readily detected in the
spleen and lymph nodes of intactmice 4 days after transfer (Fig.
1a). Strikingly, the transferred Th1 and Th2 effectors were also
detectable in the fat pads of these mice. As expected, effector
cells were also detected as circulating cells in the PBL. No sig-
nificant differences were seen between the Th1 and Th2 polar-
ized populations. Although effector cells were detectable in
intact mice, the frequency of these cells was low, and thus par-
ticularly difficult to detect in the tertiary or non-lymphoid
organs. In previous studies from our laboratory, we used
ATXBM mice as recipients to visualize the transition from
effector cell to memory cell (17, 20). To allow us to better track
the low numbers of donor cells in non-lymphoid sites, we com-
paredmigration in intact versusATXBMhosts, and we found it
to show a similar pattern. As expected, the frequency of Thy1.1
cells is somewhat higher in ATXBM mice than in intact hosts
(Fig. 1b). The paucity of host T cells clearlymakes the detection
of transferred cells more unambiguous. At later time points
after transfer, effectors are more difficult to detect in intact
hosts (data not shown). Because donor cells could be more
extensively analyzed and memory generation and persistence
followed in theT cell-deficient hosts, we showmostly data from
such hosts. We have repeated many experiments in intact ani-
mals and have always seen the same patterns.
To more readily detect cells in low frequencies, we have also
used TCR Tg mice that express green fluorescent protein
(GFP). The cells obtained from theGFPmice are bright green,
FIGURE 1. Th1 and Th2 effector cells migrate to lymphoid and non-lym-
phoid sites following adoptive transfer. Th1 and Th2 effectors were gen-
erated in vitro fromAND.Thy1.1 TCRTgnaı¨veCD4T cells. Effectorswere then
injected intravenously into naı¨ve B10.Br. hosts (a) or ATXBM B10.BR hosts (b).
After 4 days, mice were sacrificed; their organs were removed; and cells were
isolated and stained with antibodies to CD4 and Thy1.1 for analysis by flow
cytometry. The rectangles show how transferred cells were gated, and the
numbersbelow the boxes represent the percentage of donor cells detected in
spleen (SP), lymph nodes (LN), fat pads (FP), and PBL.
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which greatly facilitates their visualization. To evaluate the use
of these mice, we transferred Th1 and Th2 effectors generated
from AND.GFP naı¨ve CD4 T cells in the wild type mice. Fig.
2a confirms that the migratory patterns of these Th1 and Th2
GFP-expressing effectors are similar, and we can readily find
GFP donor effector cells in the fat pads. We also find them in
lung, liver, and peritoneal exudate as seen in later experiments.
Preliminary studies indicated that the GFP-expressing effector
cells persisted after transfer to ATXBM at levels equivalent to
their wild type counterparts.4 Fig. 2b shows the pattern of
migration of T cell subsets in the lymphoid (combined spleen
and lymph node) versus two non-lymphoid sites, the perito-
neum and abdominal fat pads. Four days following transfer of
effectors (Fig. 2b, solid bars), the peritoneum contained more
than a third of the number of cells found in the combined
lymphoid organs. Even the largely acellular fat pads contained a
significant fraction of the total (up to 1 part in 20).
Taken together, these data demonstrate that activated CD4
T cell effectors cannot only traffic to the spleen and lymph node
after transfer but that the activated cells can also migrate to
non-lymphoid sites in the absence of both antigen and inflam-
mation. No significant difference in pattern of distribution or
frequency of Th1 versus Th2 effectors was seen in repeated
experiments.
Rested Effectors Lose the Ability to Migrate to Non-lymphoid
Sites—In vitro generated CD4 T cell effectors can revert to a
resting state after further culture in the absence of antigenic
stimulation (17). As they become rested, the cells come to
express a more memory phenotype characterized by lower for-
ward scatter, loss of CD25, lower levels of surface CD44, and
higher levels of CD62L (17). Rested effectors no longer prolif-
erate to c cytokines such as IL-2, IL-4, IL-7, and IL-15,4 and
unlike effectors they do not divide upon transfer to adoptive
hosts (17). Here rested effectors are generated by culturing Th1
or Th2 effectors for an additional 2–3 days in freshmedia with-
out additional antigen or cytokines. To determine whether
migration to tertiary sites was a property dependent on the
activated state of CD4 T cell effectors, naı¨ve, Th1, and Th2
effectors and Th1 and Th2 rested effectors were transferred to
adoptive hosts, and the percent recovery of transferred donor
cells in various organs was determined based on the frequency
of donor cells and total cell recovery from each organ (Fig. 2).
This calculation makes comparison among experiments possi-
ble because the number of transferred cells often varied with
each group, and because effectors were numerous, whereas
rested effectors (especially Th1) were more rare. Earlier exper-
iments established that recovered cells were directly propor-
tional to transferred cells over a broad range (17).
By comparing recipients of these different subsets, it is clear
that rested effectors, like naı¨ve cells, do not appear in the PECor
fat pads 4 days after transfer. This result is representative of
effector, naı¨ve, and rested effector migration upon adoptive
transfer seen in over four experiments. Naı¨ve CD4 T cells
were only detected in secondary lymphoid sites and not in fat
pads or PEC. Rested effectors were like naı¨ve cells and were
found only in the spleen and lymphnode (Fig. 2b, shownhere as
combined, but separate analysis shows rested effectors concen-
trated in the spleen as shown in Figs. 5 and 6). Both Th1 and
Th2 effectors were uniquely able to enter non-lymphoid sites.
Because rested effectors were not found in PEC or fat pads, we
conclude that as effectors return to rest they quickly lose their
ability to migrate to these non-lymphoid sites. The patterns of
migration were the same irrespective of the number of cells
transferred (not shown). For all subsets, the polarization of the
cells to Th1 or Th2 profiles had little effect on their potential to
migrate to different organs.
Effectors Display Enhanced Expression of AdhesionMolecules
Relative to Rested Subsets of CD4 T Cells—The migration of
different CD4 subsets to secondary versus tertiary sites is
expected to be regulated by adhesion molecules, selectins, and
chemokine receptors. Therefore, we examined the expression
of cell surface receptors/ligands by the T cell subsets evaluated
formigration to lymphoid versusnon-lymphoid sites (Fig. 3 and
Fig. 4). We evaluated the effect of transfer on expression of
CD44 and CD62L molecules and examined expression by long
term resting memory cells from spleen and lymph nodes
derived from transfer of Th1 and Th2 effectors as described
previously (17). Such memory cells are concentrated in lymph-
oid organs, particularly the spleen (Fig. 3). We hoped this anal-
ysis would point the way to candidate pathways regulating the4 G. Huston and S. L. Swain, unpublished data.
FIGURE 2. Effectors but not naı¨ve cells or rested effectors of CD4 T cells
are found in tertiary sites.CD4naı¨ve T cells, Th1andTh2effectors, andTh1
and Th2 rested effectors were generated in vitro from AND.GFP TCR Tg and
transferred intravenously to ATXBM hosts as described in Fig. 1. After 4 days,
peritoneal exudate cells were collected; the lymphoid organs (spleen (SPL)
and LN) and fat pads were removed and analyzed by flow cytometry for per-
centage of donor cells. Donor cellswere identified by gating on simultaneous
expression of CD4 andGFP and are shownwithin the rectangles. The numbers
below the boxes represent the percentage of donor cells detected in spleen
(SPL) lymph nodes (LN) fat pads (FP) and peripheral blood (PBL) (a). Percent
recovery was calculated as the absolute number of CD4/GFP cells recov-
ered per organ divided by the total number of cells transferred (b). The data
show the mean S.D. of three mice per group.
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unique ability of effectors to migrate to non-lymphoid sites,
which is dramatically reversed as cells become resting in vitro.
As expected from previous studies (17), Th1 and Th2 effec-
tors were large activated cells with high forward versus side
scatter and high expression of CD25, whereas naı¨ve and rested
effectors were smaller cells with no CD25 expression (not
shown). We first examined CD62L and CD44 expression
because these are known to be involved in migration and are
standard markers used to identify T cell subsets (Fig. 3). We
found that the mean fluorescence intensity and pattern of
expression of transferred effectors (before transfer) was
retained at 4 days post-transfer in the spleen, PEC, and fat pads,
although only the effector populations were represented in the
non-lymphoid organs. Naı¨ve cells expressed high levels of
CD62L and low levels of CD44 both before and after transfer.
Highly activatedCD4T cell effector cells, expressed low levels
of CD62L and high levels of CD44. Rested effectors shifted their
pattern somewhat over the 4 days. They still expressed high
CD62L but displayed intermediate CD44 levels, which were
lower than those expressed before transfer, consistent with a
continued progression to a more resting state.
We next analyzed the putative memory cell population
retained 30 days after transfer for change in CD62L and CD44
expression. Fig. 3 compares expression on recovered donor
cells after effector transfer at day 4 and day 30 post-transfer.
The donor cells, derived fromTh1 andTh2 effectors, recovered
from spleen and lymph node, had reverted to a CD62L moder-
ate to high CD44 moderate phenotype, which is characteristic
of resting memory cells. At this time there were no donor cells
recoverable in the fat pads as indicated by the asterisks in Fig. 3.
These results were observed repeatedly. These results suggest
that the activated effectors are unique in their very low expres-
sion of CD62L and in the highest expression of CD44, suggest-
ing this pattern could contribute to the unique and transient
migration of effectors to tertiary non-lymphoid sites.
We also analyzed expression of a number of other adhesion
molecules by cell surface staining. Among those, the integrin
chains CD18 and CD11a and the ligand for P-selectin, CD162,
were high on effectors and lower on resting cells, including
naı¨ve, rested effectors, andmemory cells as seen in Fig. 4a. Thus
the high but transient expression on effectors of very highCD44
and high CD18, CD11a, and CD162 and loss of CD62L are
correlated with the transient ability of effectors to migrate to
PEC and fat pads.
FIGURE 3. Phenotype of CD4 T cell subsets before and after transfer.
Donor cells were isolated as described for Fig. 2, and their expression of
CD62L and CD44 was determined. Subsets were transferred to ATXBM hosts,
stained with fluorochrome-conjugated antibodies, and analyzed in various
organs for 4 days and 30 days after transfer. Donor cells were identified by
co-expression of CD4 and GFP, and expression of CD62L or CD44 was deter-
mined. The graphs show the mean fluorescence intensity of CD62L or
CD44 expression on gated donor cells. The bars represent themean S.D.
of three mice per group for spleen (SPL), peritoneal exudate cells (PEC),
lymph nodes (LN), and fat pads (FP). The level of expression of CD62L and
CD44 on naı¨ve, effectors, and rested effectors before transfer is shown as
a comparison. a, expression of CD62L (left) and CD44 (right) on CD4 T cell
subsets before and 4 days after transfer. Expression was determined by FACS
and is expressed as mean fluorescence intensity. Each bar is the mean S.D.
of threemice. Themissing bars for naı¨ve andRETh1 andRETh2denote no cells
recovered in that group and are shown by an asterisk. b, expression of CD62L
and CD44 on transferred Th1 and Th2 effectors for 4 (solid bars) and 30 days
after transfer. No cells were detected in the fat pads at 30 days and are indi-
cated by an asterisk.
FIGURE 4. Adhesion molecule expression but not chemokine receptor
expression correlates with ability to migrate to tertiary sites. a, expres-
sionof apanel of adhesionmoleculeswasdeterminedonCD4 T cell subsets,
including naı¨ve, effectors (Eth), and rested effectors (REth) and also memory
(Mem) cells recovered 6weeks after transfer of effectors toMHCclass II knock-
outmice. Those that were highest on effectors, CD18, CD11a, and CD162, are
shown as the mean fluorescence intensity. b, chemokine receptor RNA
expression by CD4 T cells subsets was determined by RNase protection
assays. Results represent the mean relative RNA expression determined in
3–4 separate experiments with S.E. The values for naı¨ve, Th2 effectors, and
Th2 rested effectors and Th2 memory are shown. Th1 counterparts were
examined at the same time and were very similar, although Th1 rested effec-
tors expressed less CCR2 than Th2, Th1 effectors expressed less CCR4 and
more CCR5 than their Th2 counterparts, and Th1 memory expressed less
CXCR5.
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We also evaluated shifts in the pattern of chemokine
receptor expression by RNase protection to see if expression
at the RNA level would correlate with the pattern of migra-
tion. Fig. 4b shows the compilation of data from 3 to 4 exper-
iments per population for naı¨ve and Th2 subsets. The only
unique feature of effectors that migrate to tertiary sites ver-
sus the naı¨ve and rested effector populations, which do not,
was a slightly increased expression of RNA for CCR4 and
CCR5. Naı¨ve and memory cells expressed high levels of
CCR7 and CXCR4, but this was not true of rested effectors.
Rested effectors expressed the highest levels of CCR2. Th1 sub-
sets showed a similar pattern for most receptors, and impor-
tantly, no unique expression of any of the receptors on Th1
effectors versus the resting populations was noted. Thus no
particular chemokine receptor was correlated with the unique
ability of effectors to migrate to the non-lymphoid sites. This is
perhaps expected, because the transfers we did were into nor-
mal, unimmunized mice where there would be only basal con-
stitutive chemokine production.
Donor Cells Remain in Lymphoid Organs as Memory Cells
but Disappear from Tertiary Sites Over Time—We wanted to
determine whether effectors in tertiary sites became resting
and persisted like those that becamememory cells in secondary
lymphoid sites. The migration of GFP effector cells to both
lymphoid organs and tertiary sites after adoptive transfer
allowed us to compare whether the memory cells that devel-
oped persisted equally in all organs. We followed the percent
recovery of transferred Th2 effectors and Th2 rested effectors
in the spleen, LN, and fat pads over 30 days (Fig. 5a). The data
are represented as log % recovery.
Both effector and rested effectors persisted in secondary sites
for 4 weeks with a slow decline that was somewhat more pro-
nounced in the effector population. The rested effectors per-
sistedwith onlyminor decreases butwere never found in the fat
pads. The fat pad data are not shown for rested effectors
because they were below the level of detection. In contrast, the
effector cells persisted in the fat pads for about 3weeks and then
declined rapidly so that they were no longer detectable by 30
days. This suggests that the donor populations decaymore rap-
idly in the tertiary site. In a separate experiment we also ana-
lyzed the relative recovery of different donor subsets at day 4
versus day 30 (Fig. 5b). Naı¨ve and both Th1 and Th2 rested
effectors went to the spleen and persisted there, but they were
not found in fat pads or PEC at days 4 or 30. Th1 and Th2
effectors were highly represented in both the spleen and in both
tertiary sites at day 4 (Fig. 5b, dark bars). Donor cells from
effectors disappeared by day 30 fromPEC and fat pads but were
still found in the spleen. Because the donor cells are retained in
secondary but not tertiary sites, it appears that thememory cells
in the two different types of locations are not in equilibrium and
suggests that memory cells do not circulate between lymphoid
organs and tissues in noninflammatory conditions. It also
appears that persistence of memory is regulated by the location
of the cells.
Antigenic Challenge of Resting Donor Cells in Vivo Leads to
Effectors, Which Migrate to Tertiary Sites—The data in Fig. 5
demonstrated that residual donor cells were not found in
appreciable numbers in tertiary sites by 30 days after transfer.
We thus wanted to visualize whether in situ stimulation of rest-
ing donor cells in secondary sites would lead to their activation
and the reacquisition of the capacity tomigrate to tertiary sites.
We reasoned that with optimal stimulation naı¨ve cells would
become primary effectors (like those we generate in vitro), as
demonstrated previously (6, 21), and that donor cells remaining
after effector transfer, which now were memory cells (17, 20),
would become secondary effectors. In each case, once fully acti-
vated, they might be able migrate to PEC, fat pads, and other
tertiary sites. Recipients of naı¨ve cells and Th2 effector or Th2
rested effector cells, introduced 4 weeks previously, were stim-
ulated with or without peptide antigen in adjuvant, and the
percent recovery of donor cells was determined 4 days later
(Fig. 6a). In all recipients, treatmentwith adjuvantwithout anti-
gen (Fig. 6a,Ag group) did not change the distribution of the
cells from that before challenge (not shown but compare with
Fig. 2). Theywere found only in spleen and LN and could not be
detected in the PEC or fat pad. In contrast, immunization with
antigen changed the migratory pattern of the naı¨ve, rested
effectors, and effectors (now rested effectors). In all these
groups, the cells migrated to fat pads and PEC. However, in
recipients of naı¨ve cells, priming with Ag led to substantial
expansion of donor cells and their appearance in PEC and to a
lesser but significant extent (comparable with the % recovery in
the earlier transfer of effector experiments) in the fat pads.
Thememory cells generated by transfer of either effectors or
rested effectors expanded dramatically in response to antigen
in adjuvant (Fig. 6a). Within the secondary sites, total recovery
FIGURE5.Donormemorycellsderived fromeffectors remain in lymphoid
organs but disappear from tertiary sites over time. a, Th2 effectors and
rested effectors were generated as described for Fig. 2, transferred to ATXBM
hosts, and their numbers followed by analyzing co-expression of CD4 and
GFP in various organs on 4, 19, and 30days after transfer. The positive and the
percent recovery were calculated for each organ as described. The bars rep-
resent the mean  S.D. of four mice assayed for each group. Data are dis-
played as log values. No donor cells were detectable in the fat pads (FP) of
mice receiving rested effectors, and so those values are not shown. b, naı¨ve,
Th1 and Th2 effectors, and rested effectors were transferred to groups of
ATXBMmice, and recovery was determined on days 4 (dark bars) and day 30
(lighter bars). The bars represent the mean S.D. of four mice assayed indi-
vidually within each group.
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was highest in spleen as compared with lymph node. Following
priming (4 days), the transferred effector cells (in situmemory
cells) were also now well represented in fat pads and perito-
neum. This suggests that the in vivo generated primary and
memory effectors had similar migratory properties as the pri-
mary in vitro generated effectors analyzed in Fig. 2 and Fig. 5.
Thus antigen challenge activated all CD4 T cells subsets in
vivo and promoted their influx into tertiary sites by 4 days.Mice
that received naı¨ve cells or rested effectors showed the highest
percentage of cells in the peritoneal cavity. It should be noted
that in this case of in vivo priming, both antigen and inflamma-
tion are present. The recipient mice receiving rested effectors
were challenged with peptide in IFA. Because the peptide/ad-
juvant is introduced intraperitoneally, the peritoneum is a
potential site of inflammation.
The Kinetics of Development of Effectors with Ability to
Migrate to Tertiary Sites—Previous studies have suggested the
peak of primary effector cell generation in vivo is seen at 6–7
days based on number, cytokine production, and the ability to
migrate to a site of infection and inflammation (6, 22). Second-
ary ormemory effectors required only 3–4 days to develop (21).
To determine and compare the kinetics of the generation of
effectorswith the capacity tomigrate to tertiary sites fromnaı¨ve
and memory cells, we compared the recruitment of naı¨ve cells
with tertiary organs after a primary immunization with the
recruitment of memory cells, resulting from the transfer of in
vitro generated effectors, upon secondary challenge with anti-
gen. For the primary response, we used the lung as a tertiary
site, because peptide in the strong inflammatory adjuvant, CFA,
was introduced intraperitoneally, and we wanted to look at an
alternate non-lymphoid site least likely to contain antigen and
to be inflamed. As shown in Fig. 6b, the percent recovery based
on the original number of transferred cells in mice given naı¨ve
cells and injected with PCCF in CFA increased with time and
peaked in the lymphoid organs (both spleen and lymph nodes)
7 days after injection. This correlates very well with our pre-
vious studies that indicated the kinetics of peak of effector
generation as indicated by both donor cell recovery (6) and
the cytokine secretion by in vivo effectors (6, 23). Because we
immunized with PCCF peptide rather than whole protein,
we reasoned that antigen would persist for only a short time.
Indeed very large numbers of cells were found in the PEC, the
most in any site, consistent with the possibility that inflam-
mation enhanced effector cell recruitment. However, the
lung also was the source of a substantial population of donor
effectors at day 7. We did not look at fat pads because of their
location relative to antigen/adjuvant injection.
By 15 days donor cells in the primed recipients of naı¨veCD4
T cells were beginning to decline in the PEC and lung. Recipi-
ents with memory cells derived from transferred effectors were
primed with peptide in incomplete adjuvant that contains no
heat-killed bacteria and is largely noninflammatory.5 At day 30
after initial transfer, no cells were detected in tertiary sites (PEC
and fat pads). The 1st day after challenge, a few cells could be
detected in PEC, and the peak recovery was seen by day 3 or 4.
In tertiary sites the cell numbers decay noticeably after their
peak, suggesting thatmemory effectors as well as primary effec-
tors decay in tertiary sites in situ.
DISCUSSION
The results presented here suggest that resting cells, includ-
ing rested effector cells and memory cells, do not migrate or
recirculate to tertiary non-lymphoid sites in the absence of
inflammation and that the ability of CD4 T cells to enter such
sites is restricted to very recently activated effectors (generated
either in vitro or in vivo) and is an intrinsic, but transient, prop-
erty of such effectors.Once in such tertiary sites, the transferred
cells revert to a resting state and decline with time at a rate
faster than the corresponding cells in secondary lymphoid
5 L. Haynes, S. Eaton, and S. L. Swain, unpublished data.
FIGURE 6. In vivo generated effectors migrate to tertiary sites. a, in vivo
generated effectors go to tertiary sites. Naı¨ve, Th2 effectors, and Th2 rested
effectors derived from AND.GFP TCR Tg mice were transferred into ATXBM
hosts and allowed to return to rest. After 30 days, recipients were injected
intraperitoneally with 5 M PCCF in IFA, whereas mice receiving naı¨ve cells
were injected with 5 M PCCF in CFA (Ag). Four days after immunization,
when the Ag-specific cells have again differentiated into effectors (naı¨ve) or
secondary effectors, mice were sacrificed and their organs removed. Donor
cells were enumerated in each sample by flow cytometry as described. The
graphs show themean S.D. of the percent recovery calculated as described
for 3–4mice per group. As a control, mice that had received naı¨ve cells, effec-
tors, or rested effectors 30 days previously were treatedwith adjuvant but no
antigen (Ag). b, kinetics of in vivo generation of migrating effectors. The
peak of memory cell numbers in non-lymphoid sites occurs earlier than the
influx of effector cells to those sites. AND.GFP TCR Tg naı¨ve cells were trans-
ferred intoATXBMhosts and immunizedwith88gofPCCFemulsified inCFA
intraperitoneally (left). At 1, 4, 7, and 15 days after immunization, mice were
sacrificed, and spleen, lymph node (LN), peritoneal exudate, and lung were
removedand isolated cells analyzed for thepresenceof CD4/GFP T cells by
flow cytometry. The graph shows themean S.D. percent recovery of CD4/
GFP T cells at different days after immunization. Right, Th2 effectors derived
from AND.GFP TCR Tgmice were transferred into ATXBM hosts and rested in
vivo for 30 days (day 0 on graph). Mice receiving effectors were then injected
intraperitoneally with 88 g of PCCF in IFA and sacrificed at various days
post-immunization. The percent recovery of CD4/GFP T cells is shown for
each time point. The data represent the mean S.D. of 3–4 mice per group.
Migration of Activated and Resting T Cells
6112 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282•NUMBER 9•MARCH 2, 2007
 by guest on D
ecem
ber 17, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
organs, suggesting there is no recirculation of resting cells
between the lymphoid andnon-lymphoid sites in the absence of
inflammation.
Effectors Migrate to Tertiary Sites under Noninflammatory
Conditions—CD4T cells in different activation states localize
to distinct sites in vivo. We used a TCR transgenic model to
generate homogeneous, well defined populations of naı¨ve, Th1
and Th2 effector, and corresponding rested effector popula-
tions to pinpoint which subsets had the ability to migrate to
non-lymphoid sites in the absence of either antigen or inflam-
mation. Effectors are highly activated, and they migrate effi-
ciently to non-lymphoid organs following adoptive transfer.
We recovered donor cells in fat pads and the peritoneum. This
suggests that migration to tertiary sites is inherent to the acti-
vation state of the cell, because effectors were detected in the
peritoneal cavity and the fat pads in unimmunized recipients,
which had no reason to have above background levels of inflam-
mation. These data are in agreement with the results obtained
by Masopust et al. (14) studying the response of CD8 T cells
after systemic infection with vesicular stomatitis virus (VSV). It
was demonstrated that VSV-specific CD8 T cell effectors,
generated in situ, can migrate to various non-lymphoid sites
such as the kidney, lung, and fat pad after viral infection (14).
However, in the VSV study, the host is infected and so inflam-
mation and traces of antigen in tertiary sites are hard to rule out.
An earlier study had also seen a widespread appearance of
responding cells in many sites during an influenza infection
(13). Similarly, using an adoptive transfer system, CD4 T
effector cells were found disseminated to the liver, lungs, and
lamina propria after intravenous injection of specific peptide
antigen emulsified in adjuvant (11). Our studies provide defin-
itive evidence that neither antigen nor inflammation is needed
for this widespread dissemination of effectors.
It is interesting to speculate on the possible positive and neg-
ative consequences of effectors entering non-lymphoid tissues.
On the positive side, this would ensure that infected cells, wher-
ever they might be, would be found by the widespread effectors
and presumably destroyed. Also, because effectors persist for
several weeks, they could provide a widespread protection
against reinfection. On the negative side, entry of effectors to
some tissues, where tissue-specific antigens are not normally
exposed to the immune surveillance, might increase the
chance of initiation of tissue-specific autoimmunity, espe-
cially if there were to be a cross-reaction between the pathogen
inducing the effectors and a tissue-specific antigen. The tran-
sience of the ability of effectors to migrate to noninflamed ter-
tiary sitesmay have been selected for because of such dangers of
autoimmune induction and damage.
Our studies showed a strong correlation between a very high
level of activation and expression of high levels of adhesion
molecules (CD44, CD11a, and CD18) and the selectin ligand
CD162 and low levels of CD62L with the ability of the effectors
to disseminate. A few days of incubation of the effectors in vitro
so they became rested effectors reversed these expressions to a
large extent and also dramatically reversed the migration on
transfer of the cells. This did not represent an impairment of
cell function because the rested effectors persisted well (some-
what better than the effectors; see Fig. 5), and they responded
well to priming with peptide 30 days later (Fig. 6). Chemokine
receptor expression, at least as reflected in RNA levels, did not
show any similar correlation. This is not surprising inasmuch as
chemokine expression (except for the constitutively expressed
homeostatic chemokines) is not expected to be high in the
recipients, which have received no antigen or adjuvant.
Further studies will be needed to determine the contribu-
tions of individual adhesion molecules and selectins to this
non-lymphoid migration. CD44, CD11a, CD18, and P-selec-
tin-ligand interactions have been demonstrated previously
to regulate recruitment to sites of inflammation (7, 8, 24),
and loss of CD62L has also been functionally associated with
such migration (25).
In earlier studies it was found that both the CD8 andCD4T
cell populations persisted for months in non-lymphoid organs
after viral infection, suggesting that long livedmemory cells can
remain in tertiary sites ready for reexposure with antigen (11,
14, 26). In that case the tertiary site was the site of infection,
viral replication, and much inflammation. In contrast, our
results suggest that CD4 T effector cells that migrate to terti-
ary sites persist only for a limited time and then decline to
undetectable levels by 4 weeks (Figs. 5 and 6a). We saw similar
indications of preferential decay in tertiary sites, even following
in situ stimulation with peptide antigen and adjuvant (Fig. 6b).
Further studies will be needed to assess whether decay is
delayed if inflammation and/or antigen is present. It may make
sense in balancing the positive and negative aspects of having
effectors and their rested counterparts widely disseminated
that the population stays long enough to outlast an infection
passing through the community, but not much longer.
Implications for Memory Cell Recirculation—After 30 days,
CD4memory T cells in this model were detected only in sec-
ondary lymphoid organs no matter what their origin (from
naı¨ve, effectors, or rested effectors). This seems to be incom-
patible with suggestions that memory cells recirculate through
peripheral tissues as suggested previously byMackay et al. (27).
The memory cells in these studies displayed preponderance in
spleen and LN, and the cells in those secondary organs did not
seem to be in equilibriumwith those in tertiary sites, where they
were no longer detectable. This suggests that memory cells
either recirculate differently and/or may not necessarily recir-
culate significantly. Rested effectors, which are on their way to
beingmemory cells (17), migrate similarly to other resting cells.
They could migrate to the spleen and LN (Fig. 2 and Fig. 6) and
after they reverted to memory cells (by day 30), and they gave a
greater response to antigen in IFA than naı¨ve cells and a vigor-
ous response to the peritoneal cavity by day 4, even though they
were initially detected only in the spleen and lymph nodes.
The migratory properties of memory T cells have been diffi-
cult to elucidate, partly because of the difficulty in defining
memory cell populations and an inability to track individual
cells. For example, Lanzavecchia and co-workers (33) have sug-
gested that two subsets ofmemory cells can be defined based on
data collected from circulating antigen experienced T cells
recovered from the blood. The CCR7 population is termed
“central memory,” and these are predicted to migrate to sec-
ondary lymphoid organs where SLC or ELC is well expressed.
The CCR7 cells are termed “effector memory” and are also
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defined by high levels of expression of adhesion molecules
LFA-1 and VLA-4 (33). Effector memory is the one that is
expected to be in non-lymphoid sites. However, our recent
results in an influenza model suggest some CD4 T cells in the
lung still retain CCR7 (6), so these definitions may not be firm.
The effector memory cells could be analogous to those long
lived cells found in non-lymphoid sites months after exposure
to virus or antigen in adjuvant as has been described in several
studies (11, 14, 26).
Long after an infection, most memory cells are found in the
spleen. It has been suggested that the spleen acts as a reservoir
for memory T cells because cells circulating through the blood
are emptied directly into this lymphoid organ via the central
arteriole (34). In the past, it was suggested that memory cells
recirculate from the tissues back into lymphoid organs (27, 35),
although others have considered the possibility that some
memory cells remain at a low frequency within tertiary sites,
without being part of a recirculating pool, and expand there
upon re-exposure to antigen (36). Because the memory cells in
the tertiary sites in our experiments decayed to undetectable
levelsmore quickly than those in secondary sites, our results are
most compatible with the latter viewpoint that suggests sepa-
rate compartments exist in secondary versus tertiary sites with
little recirculation between them.
Life Span of Effectors and Rested Effectors Is Influenced by
Site—Is the decay of cells in different organs influenced by the
environment? The shorter life span of the CD4 T cell popula-
tion in the tertiary sites could be the result of different proper-
ties of the cells themselves or, alternatively, of the different
milieu of the tertiary versus secondary component. We have
recently found that the successful transition of CD4 effector T
cells to long lived memory cells and their persistence over the
1st week is dependent on IL-7 (37), and this is consistent with
other recent studies (29). The in vivo expression of IL-7 has not
been established, but it is thought to be primarily produced
constitutively by stromal cells in the thymus, bonemarrow, and
perhaps other lymphoid tissue. We are currently exploring
whether differences in the availability of IL-7 could explain
what appears to be differences in memory CD4T cell survival
in secondary versus tertiary sites.
In Vivo Generated Primary and Memory Effector Kinetics—
The ability tomigrate to tertiary sites was restricted to the peak
of effector activity inasmuch as resting effectors for 3 days
caused them to lose this ability. Memory cells present after 30
days were not found in tertiary sites, and based on earlier trans-
fer experiments (34), it seems that memory cells also do not
have the capacity to enter tertiary sites after transfer. After
boosting, memory cells redeveloped the capacity to go to terti-
ary sites in 3–4 days, about the time they redevelop effector
activity based on state of activation and cytokine production
(21). This suggests that although memory cells can rapidly
secrete cytokines after restimulation with antigen (38), they do
not have the full spectrum of activities of effector cells. The fact
that the restimulated memory cells are found first in lymphoid
sites and would take several days to become effectors able to
migrate to the sites of infectionmay explain the greater protec-
tive ability of effector cells over memory cells in a number of
infectious disease models (39, 40).
Recent studies suggest that effectors that reach tertiary sites
during an infectionmay remain in those sites in sufficient num-
bers and perhaps in a more activated form (6, 26) like the effec-
tor memory proposed by Lanzavecchia and co-workers (33).
Some recent studies support the concept that CD8 T cells in
tertiary sites, like the lung, can rapidly respond and provide
superior protection (41), whereas others support an equal or
greater general functionality of memory with the central mem-
ory phenotype (42, 43). Our studies suggest that CD4 effector
T cells that reach noninflamed tertiary sites can revert to a
resting phenotype, and because they decay more rapidly than
those in secondary lymphoid sites, protective memory from
CD4 Tmemory cells in such sites may be of limited duration.
Further understanding of the functional potential of memory
CD4 T and CD8 T cells in different locations is needed to
determine whether there are differences between these cells in
this regard and also to determine whether prolonged antigen
stimulation in some tertiary sites can contribute to long term
maintenance of cells in an activated site in some infections.
In summary, we have found that as CD4 T cell subsets dif-
ferentiate, there is a distinct and transient effector state during
which they can migrate to noninflamed tertiary sites. This dis-
persal at the peak of the response could result in a transient
CD4 T cell response in the tertiary sites. This process is
strictly regulated, because of the fact that as soon as effectors
become resting they lose their ability to migrate to tertiary
sites and because the cells that do become memory in those
sites decay over several weeks.
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